tradingkey.logo

PharmaCyte Biotech Inc

PMCB

1.000USD

0.000
Horário de mercado ETCotações atrasadas em 15 min
6.90MValor de mercado
1.08P/L TTM

PharmaCyte Biotech Inc

1.000

0.000
Mais detalhes de PharmaCyte Biotech Inc Empresa
PharmaCyte Biotech, Inc. is a biotechnology company. It is focused on developing cellular therapies for cancer, diabetes, and malignant ascites based upon a cellulose-based live cell encapsulation technology known as Cell-in-a-Box. Its product candidate is referred to as CypCaps. The Cell-in-a-Box encapsulation technology potentially enables genetically engineered live human cells to be used to produce various biologically active molecules. It is advancing clinical research and development of new cellular-based therapies in oncology and diabetes. It is also focused on developing therapies for pancreatic and other solid cancerous tumors by using genetically engineered live human cells. Its product candidate for the treatment of diabetes consists of encapsulated genetically modified insulin-producing cells. It is also focused on the benefits of the Cell-in-a-Box technology to develop therapies for cancer that involve prodrugs based upon certain constituents of the Cannabis plant.
Informações da empresa
Código da empresaPMCB
Nome da EmpresaPharmaCyte Biotech Inc
Data de listagemSep 11, 2003
CEOMr. Joshua N. (Josh) Silverman
Número de funcionários2
Tipo de títulosOrdinary Share
Fim do ano fiscalSep 11
Endereço3960 Howard Hughes Parkway, Suite 500
CidadeLAS VEGAS
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited States of America
Código postal89169
Telefone19175952850
Sitehttps://pharmacyte.com/
Código da empresaPMCB
Data de listagemSep 11, 2003
CEOMr. Joshua N. (Josh) Silverman
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Jonathan L. Schechter
Mr. Jonathan L. Schechter
Independent Director
Independent Director
50.00K
--
Mr. Carlos A. Trujillo, CPA
Mr. Carlos A. Trujillo, CPA
Chief Financial Officer
Chief Financial Officer
10.40K
--
Dr. Michael M. Abecassis, M.D.
Dr. Michael M. Abecassis, M.D.
Independent Director
Independent Director
--
--
Mr. Wayne R. Walker
Mr. Wayne R. Walker
Independent Director
Independent Director
--
--
Mr. Robert Weinstein
Mr. Robert Weinstein
Independent Director
Independent Director
--
--
Mr. Joshua N. (Josh) Silverman
Mr. Joshua N. (Josh) Silverman
Interim Chairman of the Board, Interim Chief Executive Officer and Interim President
Interim Chairman of the Board, Interim Chief Executive Officer and Interim President
--
--
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Jonathan L. Schechter
Mr. Jonathan L. Schechter
Independent Director
Independent Director
50.00K
--
Mr. Carlos A. Trujillo, CPA
Mr. Carlos A. Trujillo, CPA
Chief Financial Officer
Chief Financial Officer
10.40K
--
Dr. Michael M. Abecassis, M.D.
Dr. Michael M. Abecassis, M.D.
Independent Director
Independent Director
--
--
Mr. Wayne R. Walker
Mr. Wayne R. Walker
Independent Director
Independent Director
--
--
Mr. Robert Weinstein
Mr. Robert Weinstein
Independent Director
Independent Director
--
--
Mr. Joshua N. (Josh) Silverman
Mr. Joshua N. (Josh) Silverman
Interim Chairman of the Board, Interim Chief Executive Officer and Interim President
Interim Chairman of the Board, Interim Chief Executive Officer and Interim President
--
--
Detalhamento da receita
Sem dados
Sem dados
Por Empresa
Por Região
Sem dados
Distribuição de ações
Atualizado em: ter, 13 de mai
Atualizado em: ter, 13 de mai
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Intracoastal Capital, L.L.C.
7.68%
The Vanguard Group, Inc.
2.83%
Geode Capital Management, L.L.C.
2.02%
Equitec Proprietary Markets, LLC
1.21%
Asher (Daniel B)
1.21%
Other
85.05%
Investidores
Investidores
Proporção
Intracoastal Capital, L.L.C.
7.68%
The Vanguard Group, Inc.
2.83%
Geode Capital Management, L.L.C.
2.02%
Equitec Proprietary Markets, LLC
1.21%
Asher (Daniel B)
1.21%
Other
85.05%
Tipos de investidores
Investidores
Proporção
Corporation
7.68%
Investment Advisor
4.57%
Individual Investor
2.85%
Investment Advisor/Hedge Fund
2.60%
Hedge Fund
1.14%
Bank and Trust
0.05%
Other
81.10%
Participação acionária institucional
Atualizado em: ter, 1 de jul
Atualizado em: ter, 1 de jul
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q2
66
1.30M
18.90%
-536.38K
2025Q1
71
1.30M
18.90%
-631.78K
2024Q4
75
1.52M
21.80%
-704.25K
2024Q3
81
1.75M
23.16%
-1.87M
2024Q2
84
1.91M
21.34%
-3.77M
2024Q1
81
1.85M
20.70%
-3.82M
2023Q4
82
1.98M
21.84%
-3.87M
2023Q3
81
2.90M
23.35%
-2.45M
2023Q2
83
2.99M
16.94%
-4.58M
2023Q1
79
7.49M
40.43%
+256.98K
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Intracoastal Capital, L.L.C.
527.38K
7.68%
--
--
Dec 31, 2024
The Vanguard Group, Inc.
194.52K
2.83%
+2.13K
+1.11%
Mar 31, 2025
Geode Capital Management, L.L.C.
138.94K
2.02%
-25.80K
-15.66%
Mar 31, 2025
Equitec Proprietary Markets, LLC
82.73K
1.21%
--
--
Mar 31, 2025
Asher (Daniel B)
82.73K
1.21%
--
--
Dec 31, 2024
Schechter (Jonathan L)
50.00K
0.73%
--
--
Feb 01, 2025
Silverman (Joshua N.)
50.00K
0.73%
--
--
Feb 01, 2025
Renaissance Technologies LLC
49.50K
0.72%
+200.00
+0.41%
Mar 31, 2025
Schonfeld Strategic Advisors LLC
25.50K
0.37%
-200.00
-0.78%
Mar 31, 2025
Dimensional Fund Advisors, L.P.
20.30K
0.3%
-6.54K
-24.37%
Mar 31, 2025
Ver Mais
ETFs Relacionados
Atualizado em: sáb, 2 de ago
Atualizado em: sáb, 2 de ago
Nome
Proporção
iShares Micro-Cap ETF
0%
Dimensional US Core Equity 1 ETF
0%
iShares Micro-Cap ETF
Proporção0%
Dimensional US Core Equity 1 ETF
Proporção0%
Dividendo
Um total de 0.00 USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados
KeyAI